Drug Profile


Alternative Names: Eprodisate disodium; Eprodisate sodium; Fibrillex; Kiacta; NC-503

Latest Information Update: 28 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BELLUS Health
  • Developer Auven Therapeutics; BELLUS Health
  • Class Alkanes; Anti-inflammatories; Small molecules; Sulfonic acids
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Sarcoidosis
  • Preregistration Submission Withdrawal Amyloid A amyloidosis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 Dec 2016 Discontinued - Phase-III for Amyloid A amyloidosis in USA, European Union, Russia, Israel, Peru, Mexico, India, Argentina, Turkey, Brazil, Chile, Egypt, Tunisia, Ukraine, Georgia, Japan (PO)
  • 21 Jan 2016 Auven Therapeutics and Auven Therapeutics complete a phase III trial in Amyloid A amyloidosis in countries worldwide (NCT01215747)
  • 19 May 2015 Eprodisate is still in phase III trials for Amyloid A amyloidosis in the USA, European Union, Argentina, Brazil, Chile, Egypt, Mexico, Israel, India, Peru, Russia, Ukraine, Tunisia and Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top